Condition
Vulvovaginal Candidiasis, Genital
Total Trials
4
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 3 (2)
Trial Status
Unknown2
Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07109869Phase 3Recruiting
Safety and Efficacy of Boric Acid Inserts for Treatment of Vulvovaginal Candidiasis
NCT06411314Phase 3CompletedPrimary
Efficacy and Safety of Natamycin and Lactulose Vaginal Suppositories in Treatment of Vulvovaginal Candidiasis
NCT05273333Not ApplicableUnknownPrimary
Effect of Ultra-gyn® on Vulvovaginal Candidiasis
NCT04292704Not ApplicableUnknownPrimary
A Protocol for the Role of Fractional CO2 Laser in Consolidation Treatment of Recurrent Vulvovaginal Candidiasis
Showing all 4 trials